Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting
Olema Oncology (Nasdaq: OLMA) has announced upcoming presentation of preclinical data for OP-3136, their novel KAT6 inhibitor, at the 2025 AACR Annual Meeting in Chicago. The presentation will showcase the drug's anti-tumor activity in multiple solid tumor models, including prostate, ovarian, and non-small cell lung cancer.
The research demonstrates that OP-3136 functions as a potent and selective inhibitor of lysine acetyltransferase 6 (KAT6). Dr. Gopinath S. Palanisamy will present these findings in a late-breaking poster session (LB166) on April 28, 2025, from 9:00am-12:00pm CT.
Olema Oncology (Nasdaq: OLMA) ha annunciato la prossima presentazione dei dati preclinici per OP-3136, il loro nuovo inibitore di KAT6, durante il 2025 AACR Annual Meeting a Chicago. La presentazione metterà in evidenza l'attività anti-tumorale del farmaco in diversi modelli di tumori solidi, inclusi tumore della prostata, ovarico e carcinoma polmonare non a piccole cellule.
La ricerca dimostra che OP-3136 funge da inibitore potente e selettivo dell'acetiltransferasi della lisina 6 (KAT6). Il Dr. Gopinath S. Palanisamy presenterà questi risultati in una sessione di poster a tarda rottura (LB166) il 28 aprile 2025, dalle 9:00 alle 12:00 CT.
Olema Oncology (Nasdaq: OLMA) ha anunciado la próxima presentación de datos preclínicos para OP-3136, su nuevo inhibidor de KAT6, en la reunión anual de AACR 2025 en Chicago. La presentación mostrará la actividad anti-tumoral del fármaco en múltiples modelos de tumores sólidos, incluidos cáncer de próstata, ovario y pulmón no microcítico.
La investigación demuestra que OP-3136 actúa como un potente y selectivo inhibidor de la lisina acetiltransferasa 6 (KAT6). El Dr. Gopinath S. Palanisamy presentará estos hallazgos en una sesión de carteles de última hora (LB166) el 28 de abril de 2025, de 9:00 a 12:00 CT.
올레마 온콜로지 (Nasdaq: OLMA)는 2025 AACR 연례 회의에서 OP-3136의 전임상 데이터 발표를 예고했습니다. 이 발표에서는 전립선암, 난소암, 비소세포 폐암을 포함한 여러 고형 종양 모델에서 약물의 항종양 활성을 보여줄 것입니다.
연구 결과 OP-3136은 라이신 아세틸트랜스퍼라제 6(KAT6)의 강력하고 선택적인 억제제로 작용합니다. 고피나스 S. 팔라니사미 박사는 2025년 4월 28일 오전 9시부터 오후 12시까지 CT에서 진행되는 늦은 발표 포스터 세션(LB166)에서 이 결과를 발표할 예정입니다.
Olema Oncology (Nasdaq: OLMA) a annoncé la prochaine présentation de données précliniques pour OP-3136, leur nouvel inhibiteur de KAT6, lors de la réunion annuelle de l'AACR 2025 à Chicago. La présentation mettra en avant l'activité anti-tumorale du médicament dans plusieurs modèles de tumeurs solides, y compris cancer de la prostate, cancer de l'ovaire et cancer du poumon non à petites cellules.
La recherche démontre qu'OP-3136 fonctionne comme un inhibiteur puissant et sélectif de l'acétyltransférase de la lysine 6 (KAT6). Le Dr Gopinath S. Palanisamy présentera ces résultats lors d'une session d'affiches tardives (LB166) le 28 avril 2025, de 9h00 à 12h00 CT.
Olema Oncology (Nasdaq: OLMA) hat die bevorstehende Präsentation von präklinischen Daten für OP-3136, ihren neuartigen KAT6-Inhibitor, auf dem 2025 AACR Annual Meeting in Chicago angekündigt. Die Präsentation wird die antitumorale Aktivität des Medikaments in mehreren Modellen solider Tumoren, einschließlich Prostatakrebs, Eierstockkrebs und nicht-kleinzelligem Lungenkrebs, hervorheben.
Die Forschung zeigt, dass OP-3136 als potenter und selektiver Inhibitor der Lysin-Acetyltransferase 6 (KAT6) fungiert. Dr. Gopinath S. Palanisamy wird diese Ergebnisse in einer späten Posterpräsentation (LB166) am 28. April 2025 von 9:00 bis 12:00 Uhr CT vorstellen.
- Demonstrated anti-tumor activity in multiple cancer types (prostate, ovarian, and lung cancer)
- Successfully developed a selective and potent KAT6 inhibitor
- Research selected for late-breaking presentation at major cancer conference
- Only preclinical stage data available
- No human clinical trial results yet
SAN FRANCISCO, March 25, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it will present a poster highlighting preclinical anti-tumor activity of OP-3136, a novel small molecule that potently and selectively inhibits lysine acetyltransferase 6 (KAT6), in prostate, ovarian, and non-small cell lung cancer models in a late-breaking session at the American Association for Cancer Research (AACR) Annual Meeting taking place April 25-30 in Chicago, Illinois.
Poster Presentation Details
Title: OP-3136, a selective KAT6 inhibitor, demonstrates anti-tumor activity in prostate, ovarian, and non-small cell lung cancer preclinical models
Poster/Abstract: LB166
Session: Late-Breaking Research: Tumor Biology 2
Date/Time: April 28, 2025, from 9:00am-12:00pm CT / 10:00am-1:00pm ET
Presenter: Dr. Gopinath S. Palanisamy, DVM, PhD
Additional information can be found on the AACR Annual Meeting website.
About OP-3136
OP-3136 is a novel, orally available small molecule that potently and selectively inhibits lysine acetyltransferase 6 (KAT6), an epigenetic target that is dysregulated in breast and other cancers. In preclinical studies, OP-3136 has demonstrated significant anti-proliferative activity in ER+ breast cancer models and is combinable and synergistic with endocrine therapies, including palazestrant and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. The Investigational New Drug (IND) application for OP-3136 was cleared by the U.S. Food and Drug Administration (FDA) in December 2024 and patients are currently enrolling in the Phase 1 clinical trial.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical trial. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
FAQ
What is OP-3136 and how does it work against cancer?
Which cancer types showed response to OLMA's OP-3136 in preclinical studies?
When will Olema Oncology (OLMA) present the OP-3136 data at AACR 2025?
What type of presentation will OLMA deliver for OP-3136 at AACR 2025?
